Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful completion of the first two commercial implants using its transcatheter aortic valve replacement (TAVR) product, the Trilogy heart valve system, in Hong Kong. This marks a significant milestone as the Trilogy system is the first and only approved transarterial TAVR product globally for the treatment of aortic valve regurgitation as of the announcement date.
Strategic Licensing Deal with JenaValve Technology Inc.
In January 2022, Peijia Medical struck a licensing deal with JenaValve Technology Inc., a US-based company, securing the development, manufacturing, and commercialization rights to the Trilogy heart valve system in Greater China. This strategic partnership has paved the way for Peijia Medical to expand its reach and impact in the field of cardiovascular treatments.
Clinical Trial Preparations and Technology Transfer
While a clinical trial for the Trilogy heart valve system is currently under preparation in mainland China, the technology transfer process has been successfully finalized. This progress indicates Peijia Medical’s commitment to advancing the product’s clinical application and making it accessible to a broader patient population in need of advanced heart valve treatments.-Fineline Info & Tech
